| Treatment of hyperlipidaemia with fenofibrate and related fibrates. | |
| | |
MedLine Citation:
|
PMID: 18808320 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia and combined hyperlipidaemia have been demonstrated in several clinical trials. OBJECTIVE: To review the pharmacology, lipid-lowering and extra-lipid effects of fenofibrate and to preview ABT-335, an investigational new fenofibric acid molecule. RESULTS: The effects of fenofibrate are mediated through the active metabolite fenofibric acid, and are described in detail in the paper. ABT-335 is a salt of fenofibric acid and, unlike fenofibrate, does not require first pass metabolism to the active moiety. ABT-335 is being developed for combination use with statins, and has recently completed three large Phase III randomised controlled trials in which the efficacy and safety of ABT-335 in combination with the three most commonly prescribed statins, atorvastatin, simvastatin and rosuvastatin, was evaluated in patients with mixed dyslipidaemia. CONCLUSION: ABT-335 in combination with statins may provide a safe and efficacious treatment modality that enables achievement of several therapeutic goals in patients with mixed dyslipidaemia who have high cardiovascular risk. |
| | |
Authors:
|
Theodosios Filippatos; Haralampos J Milionis |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on investigational drugs Volume: 17 ISSN: 1744-7658 ISO Abbreviation: Expert Opin Investig Drugs Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-23 Completed Date: 2008-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9434197 Medline TA: Expert Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 1599-614 Citation Subset: IM |
Affiliation:
|
University of Ioannina, School of Medicine, Department of Internal Medicine, 451 10 Ioannina, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiography Antilipemic Agents / therapeutic use* Clinical Trials as Topic Drug Interactions Drug Therapy, Combination Fluorobenzenes / therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Hyperlipidemias / drug therapy* Lipids / blood Procetofen / adverse effects, analogs & derivatives*, pharmacokinetics, pharmacology, therapeutic use* Pyrimidines / therapeutic use Sulfonamides / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid; 0/Antilipemic Agents; 0/Fluorobenzenes; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 0/Pyrimidines; 0/Sulfonamides; 287714-41-4/rosuvastatin; 49562-28-9/Procetofen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Next Document: Hug Tightly and Say Goodbye: Role of Endothelial ICAM-1 in Leukocyte Transmigration.